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Abstract The exponential accumulation, processing and accrual of big data in
healthcare are only possible through an equally rapidly evolving field of big data
analytics. The latter offers the capacity to rationalize, understand and use big data to
serve many different purposes, from improved services modelling to prediction of
treatment outcomes, to greater patient and disease stratification. In the area of infectious
diseases, the application of big data analytics has introduced a number of changes in the
information accumulation models. These are discussed by comparing the traditional
and new models of data accumulation. Big data analytics is fast becoming a crucial
component for the modelling of transmission—aiding infection control measures and
policies—emergency response analyses required during local or international out-
breaks. However, the application of big data analytics in infectious diseases is coupled
with a number of ethical impacts. Four key areas are discussed in this paper: (i)
automation and algorithmic reliance impacting freedom of choice, (ii) big data analytics
complexity impacting informed consent, (iii) reliance on profiling impacting individual
and group identities and justice/fair access and (iv) increased surveillance and popula-
tion intervention capabilities impacting behavioural norms and practices. Furthermore,
the extension of big data analytics to include information derived from personal
devices, such as mobile phones and wearables as part of infectious disease frameworks
in the near future and their potential ethical impacts are discussed. Considered together,
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the need for a constructive and transparent inclusion of ethical questioning in this
rapidly evolving field becomes an increasing necessity in order to provide a moral
foundation for the societal acceptance and responsible development of the technolog-
ical advancement.
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1 Introduction
The terms big data and big data analytics are often used within the context of
healthcare as an all-encompassing phrase referring to the use of large datasets. Their
increasingly regular use does little to signify the underlying complexity of defini-
tions, and paves the way for potential subsequent ethical and social misunderstand-
ings (Floridi 2012). Big data is defined as collections of data so large and highly
complex that its manipulation and management require the application of a series of
computing techniques—including but not limited to—machine learning and artifi-
cial intelligence (Stuart Ward and Barker 2013). Big data analytics is defined as ‘the
process of collecting, organizing and analysing large sets of data (called big data) to
discover patterns and other useful information’ (Heymann and Rodier 2004).
Within the sphere of routine healthcare and associated research, the term is often
synonymous to electronic patient records from central public authorities, large
hospitals, clinical trials, ‘-omics’ and sequencing-based outputs and their associated
banked samples, imaging, mobile phones and/or wearables. These data can be
structured or unstructured, generated from diverse sources and at diverse speed,
and in very large volumes. Big data analytics (BDA) are the collectively termed
processes that translate the big data into interpretable and potentially actionable sets
of information that can confer a competitive advantage (LaValle and Lesser 2011).
BDA have attracted attention as they have been shown to have transformational
potential for generating reliable, actionable and novel insights about the world we live
in. Positive examples have been reported in the financial services (Mayer-Schoenberger
and Cukier 2013) and in healthcare (Murdoch and Detsky 2013; Raghupathi and
Raghupathi 2014; Lee et al. 2016). For infectious diseases, BDA is useful in monitor-
ing diseases outbreaks; stratifying patients for treatment, risk exposure and treatment
outcome prediction; and for the prediction of behavioural patterns with the aim of
informing public health interventions (Darrell et al. 2015; Lee et al. 2016). Despite
these positive outcomes, the routine use of BDA is increasingly challenged with
examples of wrongful conclusions (Lazer et al. 2014), potential misuse of personal
information, well-publicised privacy breeches and ongoing profiling of individuals for
commercial purposes (Smith 2012; Richards and King 2014; Martin 2015). Often
described as unintended (Wigan and Clarke 2013), these are very real risks
(Clarke 2016). However, these risks are not always predictable or preventable,
as the context in which big data is used heavily determines which of those
problems actually occur and whether they may lead to negative consequences at
the individual and/or societal levels (Markus 2015; Zuboff 2015; Duhigg 2012).
In the field of medical ethics, the basic principles of autonomy, beneficence,
non-maleficence and justice remain relevant for BDA (Gillon 1994; Page 2012).
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However, they are tested by the differential interpretation relating to their contex-
tual application in clinical care, public health policy, administrative repurposing,
patient-generated data and research (e.g. clinical trials and/or use of metadata)
with BDA acting as a magnifying glass for potential differences and difficulties
(Bollier 2010). Furthermore, the way in which data have increasingly been
collected outside of traditional healthcare settings and shared with third parties
for research and commercial gains has also changed (Jetten and Sharon 2016).
These factors are expected to intensify further as data collection is expected to
scale up and become more distributed through ‘non-traditional’ channels with its
processing being quicker and more automated.
Given these potential issues associated with BDA and considering its increased
uptake, discussions are ongoing regarding what constitutes its ethical versus uneth-
ical use in healthcare. There are a number of studies addressing this aspect
(Mittelstadt and Floridi 2016), which is particularly pertinent in the field of infec-
tious diseases, where the impact of BDA is already tangible and is further aug-
mented by the ‘non-traditional’ data collection systems, such as wearables and
mobile phones (Vanhems et al. 2013). In this paper, we discuss some of the changes
occurring in the field of BDA in infectious diseases by comparing the traditional
model of data accumulation to the new one. We then discuss the ethical challenges
according to four headings: (i) automation and algorithmic reliance impacting
freedom of choice, (ii) big data analytics complexity impacting informed consent,
(iii) reliance on profiling impacting individual and group identities and justice/fair
access and (iv) increased surveillance and population intervention capabilities
impacting behavioural norms and practices.
2 Information Accumulation Models in Infectious Diseases and the Impact
of BDA
The traditional information accumulation model in infectious diseases remains a variant
of a hierarchical hub-and-spoke model, where well-defined smaller reporting centres
(such as GP practices or individual virologists) report to a central authority at the local
level (such as referral hospitals) or at the national level (such as Public Health England
in the UK) for the epidemiological view. The accumulated information is aggregated at
population level, processed, corrected/defined and processed again (in a number of
iterative cycles). Subsequently, actions relating to these conclusions are disseminated to
the whole system in a top-down approach. This is economical in the sense of using
defined communication channels according to established professional and well-
regulated processes, recommendations, actors and actions. In addition, there are bona
fide population data aggregators, such as national health surveys, administrative hos-
pital data and biobanks, at a local national or international level, for example the UK
Biobank in the UK and the BBMRI-ERIC in the European Union (Biobanking and
Biomolecular Resources research infrastructure–European Research Infrastructure
Consortium) (Kozlakidis 2016).
However, the information accumulation and processing steps carry an inevitable
time lag that can result in reduced response effectiveness at a public health intervention
level. The usually slow methods of assessing medical knowledge through the
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accumulation of evidence-based cases are challenged by rapidly evolving global
threats. This can have catastrophic results when dealing with infectious disease occur-
rences as was observed in the case of the recent Ebola outbreak in West Africa
(McCarthy 2016) or in the cases of the global influenza pandemics in 2008–2009
(Doshi 2009). It should be noted though that the established, global hub-and-spoke
system is still considered successful in identifying potential disease outbreaks at an
international level (Heyman and Rodier 2001; Heyman and Rodier 2004) and some
national levels (Randrianasolo 2010). The need for speed in data sharing/accumulation,
processing and advice provision in the case of unexpected/novel outbreaks was iden-
tified early on and became one of the main drivers for introducing BDA capabilities.
The initial piloted learnings were then distilled and used as improvements on the hub-
and-spoke systems (Jacobsen et al. 2016; Simonsen et al. 2016).
The above information accumulation models are most effective in the cases of
sedentary, well-defined, well-predictable populations and outbreaks. They do not
necessarily reflect the current global contextual complexity or the patchy and/or often
unstructured nature of real-time data. As such, they come under increasing stress and
criticism for lack of adaptability. Mass migrations—often resulting from emergencies
such as floods and wars—can produce conditions that exacerbate this phenomenon,
spreading infectious diseases, often in unexpected ways. Global trade, mass gatherings
and travel can introduce pathogens into new populations creating the potential to
develop into epidemics, e.g. West Nile virus introduction and spread in New York
(Fonkwo 2008), post-festival measles outbreak in Germany (Pfaff et al. 2010) and
H1N1 spread through airline transportation (Khan et al. 2009).
2.1 New Sources of Information Accumulation
Mobile phones can be used to address global and healthcare data inequities and hold
particular promise in low- and middle-income countries (LMIC) where conventional
sources of social and health-related data are often patchy, out of date or simply non-
existent (Kaplan 2006; Deville et al. 2014; Center for Global Development 2014). The
extraordinary reach and potential effectiveness of engaging mobile technologies was
demonstrated by (a) an emergency reporting system for infectious diseases surveillance
in Sichuan province, China, following the catastrophic earthquake of 2008 (Yang et al.
2009); (b) a monitoring system for the long-distance observation of tuberculosis
patients in Kenya (Hoffman et al. 2010) and (c) a guidance tool for potential Ebola
patients providing directions to the closest available health centres (Trad et al. 2015). In
the UK, a mobile phone-enabled, video-observed therapy clinical trial for adherence to
treatment for tuberculosis patients is already underway (Story et al. 2016) and under
consideration as part of an increased patient offering by the UK public health system. In
addition, a number of mobile-enabled infectious diseases diagnostic tools are currently
under development. The use of mobile phone technologies as part of mainstream
healthcare is considered largely inevitable (Dell et al. 2011).
There are many studies describing the development of different sensor technol-
ogies and wireless medical instruments (collectively termed as wearables) with the
ability to remotely monitor patients at a distance, at home or elsewhere, by
recording personal parameters such as blood pressure, heart rate, sugar levels,
vital signs, oxygen levels, body temperature, and mental well-being metrics
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(Chana 2012). The main driver behind these developments remains the need for
the early warnings for the onset of adverse health conditions and service improve-
ments coupled with costs reductions in the health sector (Page 2015a). Wearable
devices can transmit vast amounts of data sometimes in constant live streaming
modes which raises important ethical issues regarding privacy and security.
Individuals, organisations and businesses can be severely affected if third parties
access private information in an unlawful manner. Although wearable devices are
designed to promote independence, they require different levels of privacy intru-
sion to collect data, especially when recording passively, therefore making it
important to consider ethical implications from different stakeholders’ perspec-
tives (Yeslam 2015). Additionally, choice/autonomy and security/privacy risks can
be bidirectional, i.e. from pre-selected incoming data (i) equipment might be
adjusted to allow for greater provider preference as opposed to patient preference,
in the case of medication pre-order for example and (ii) risks can arise from the
outgoing information, as well as by incoming information into the device, as
malware can jeopardize patients’ health by causing some (intentional or uninten-
tional) malfunction of the device (Segura et al. 2017).
2.2 BDA Impact on Infectious Diseases
The most commonly mentioned impact of BDA in the field of infectious diseases
relates to the access and use of information contained in individual medical
records and/or collected using healthcare systems’ channels. In this context,
insights generated by routine access and use of these data, including when explicit
consent each time is not a viable option (such as in the case of large-scale,
multiple-site epidemiological studies), can potentially benefit patients, institutions,
public health as well as commercial entities. The main difference with the tradi-
tional regime relates to the scale and reach of BDA capabilities, accessing and
processing much larger numbers of medical records and more information per
record. However, the levels of access and use of the information do vary between
locations and for different purposes. In the field of infectious diseases, decision is
guided by two separate specialties’ viewpoints: epidemiology, looking at the
overall population-level health, and infectious diseases specialties (such as micro-
biology, virology) addressing the individual-level health. This is reflected in the
ethical arguments framed as autonomy versus public good, where BDA has acted
as a catalyst in the arguments on either side (Gilbert 2012; Kozlakidis et al. 2012;
Blais and White 2015).
From an individual perspective, the availability of vast amounts of information
regarding people, for example via geo-tagged social networks, makes even data
anonymization ineffective in fully protecting the identity of the data source,
making it only more difficult, yet still feasible via triangulation, to (re)identify it
(Cecaj et al. 2016). As such, the ethical imperative of transparency with regard to
the dangers of downstream data linkage and inadvertent individual identification
should be upheld. To this end, the Groupe Speciale Mobile Association (GSMA)
has developed guidelines for the appropriate use of Call Detail Record (CDR) and
Standard Messaging Services (SMS) data in emergency situations (GSMA 2013)
and updated them specifically for infectious diseases based on the experiences
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from the Ebola outbreak in West Africa (GSMA 2014) with some limited but not
extensive consideration of potential ethical implications.
From a population-level perspective, if systems are designed to rely entirely on
anonymous contributions in order to protect their original data contributors, they
might not work well either, as the element of information accountability and,
hence, transparency is affected. Especially in the case of humanitarian emergen-
cies, and certainly communicable disease outbreaks, anonymous information can
be accompanied by a climate of fear and mistrust. Information should ideally be
provided with the source location and time for full accountability and to aid
appropriate infection control (Bayham et al. 2015; Funk et al. 2009). The possi-
bility of malevolence under such a scenario, for example by spreading rumours
(intentional or unintentional), has to be taken seriously. Anonymous mobile-
enabled reporting systems within these contexts could result both in poor quality
data, and in the provision of a platform for increased community disharmony
(Cinnamon et al. 2016).
3 The BDA Impact on Infectious Diseases Ethics
The allure of these technological applications and their impact is coupled with as
yet unanswered ethical challenges. BDA-enabled infectious diseases tools could
exacerbate the tensions between individual and public good. A number of these
ethical questions are not novel; however, the scale at which they can occur and
their potential impact has now been multiplied, as a small number of decisions/
actions can now potentially affect multiple populations at different geographical
locations at the same time. At what point are individuals prepared to compromise
on some rights, such as that of privacy and autonomy, if it benefits them? Under
what circumstances in the field of infectious diseases can individuals give up some
individual benefits in order to greatly enhance public good? And, assuming that
there is a benefit to the individual directly (e.g. appropriate medical treatment
through better tailored response), to what extent should society be able to operate
without disclosure and transparency regarding decisions taken automatically
through data access and use?
3.1 Freedom of Choice
One of the key challenges in the field of BDA in infectious diseases is connected to
the difficulty for individuals to be fully aware of what happens to their data after
collection, as this might be generated in one locality, aggregated in a second,
processed in a third, and so on. In other words, the initial data often moves through
an information value chain: from data collectors, to data aggregators, to analysers/
advisors, to policy makers, to implementers. Data aggregators and analysers com-
bine the data from multiple sources and create a new picture of individuals based on
the data received (Bollier 2010). Ethical issues can arise for each segment of this
collection and distribution chain, even without utilizing any BDA on the data at all,
with the final actor/implementer using the data for purposes that can be very
different from the initial intention of the individual that provided the data.
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As more data is used at increasing scale, there are growing concerns relating to
aspects of automation, which is often associated to erosion of autonomy and a
reduction in personal choices (Hildebrandt and Rouvroy 2011). Machine learning
tries to identify relationships within big data sets and subsequently, the context in
which these identified relationships are meaningful. The difficulty in accurately
predicting any human behaviours based on such data correlations, lies in the
tendency to ignore (or normalize) the human design and inherent error and biases
in data, measures and analyses (Zuboff 2015). Furthermore, the tendencies of
automation to flatten outliers and confirm patterns, to equate correlation with
causation and to make it difficult to judge assumptions (i.e. lack of transparency)
are also problematic (Hildebrandt 2011). The ethical question then remains: under
what circumstances, if any, are such statistical approximations and reduced personal
choices acceptable? The initial use of BDA as decision support can transit into an
automated decision-making process, especially if the decision support uses have
proven medically effective. Perhaps this is an opportunity to investigate technical
mechanisms that can introduce an element of human oversight to inform and
safeguard on the ethical aspects of automation, decision support and decision-
making. In particular, the freedom of choice to opt-out or disagree with both
decision support and decision-making outcomes should be coupled with the ability
to request a second opinion that is entirely independent of the automated mecha-
nism (e.g. an independent specialist consultation) and without any potential impli-
cations on future healthcare provision. In this manner, individuals are guaranteed a
choice within existing norms and without future penalties.
3.2 Informed Consent
The reliance on algorithms for analyses in infectious diseases can introduce a gradual
reduction of general understanding of the decision-making process, as the latter
becomes an indecipherable black box (Pasquale 2015). Recognizing BDA as a com-
plex process with several contributing actors including private firms is therefore
important and requires transparency at each step (Asadi Someh et al. 2016; Martin
2015). Is it then ethical, or even at all possible, to achieve a truly informed consent in
everyday routine clinical practice and public health, on systemic data usage in the era of
BDA? Or should the model of informed consent for BDA-enabled data usage be
applied fully, only to research data and clinical trials?
In an effort to navigate through some of these complexities and in the wake of
the influenza pandemic, the WHO has advised that there must be a clear distinc-
tion between the boundaries of public-health oriented research and clinical prac-
tice. The informed consent of clinical practice carries the well-defined risk of
preceding evidence-based practice, while the research-based activities carry a
higher risk which should be made clear during the consenting process. The
implementation of BDA with the potential for reduced understanding of the
process also carries the risk of obfuscating the understanding of risk during
consenting. Distinguishing between clinical research and practice is important,
even if it is often difficult, because of the varied ways in which they are perceived
and regulated in different countries (WHO 2007). The practicality of this recom-
mendation was severely tested in the recent Ebola outbreak, where BDA-enabled
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research and clinical decision-making had to be concurrent due to the nature and
timings of the outbreak (WHOERT 2014).
In the case of viral diagnostics for example, the amount and granularity of informa-
tion provides not only the knowledge regarding potential drug resistance parameters by
the infecting organism but also the reconstruction of infectious disease outbreaks,
transforming the question of ‘who infected whom’ into ‘they infected them’, i.e. from
the more general to the definitive form (Escobar-Gutierrez et al. 2012; Pak and
Kasarskis 2015; Bosch et al. 2016). In this context, the informed consent should be
able to articulate the potential for group-level identification of infectious diseases
through BDA. Most informed consent forms used currently in clinical practice identify
personal risks and ignore group-level risks, perhaps as the latter are more challenging to
identify and quantify.
3.3 Profiling and Justice
In order to create actionable and interpretable recommendations, aggregated popu-
lation data are used to stratify the population into smaller groups to support realistic
public health interventions. This method is called profiling and can occur by
classifying individuals into groups, based on any given characteristic, including
race, ethnic group, gender, and socio-economic status (LaBeaud et al. 2008; Newell
and Marabelli 2015). However, the patient profiling in the field of infectious
diseases is not always as straightforward. An important ethical aspect is the
transition of an infected patient, from a vector of a disease to a potential victim,
to a potential transmission node. Although technically, the link between these states
can now be proven unequivocally and at increasing scale through modern diagnos-
tics, there is a paucity on social science and ethics research exploring how these
patients understand and react to these transitions—and in relation to therapeutic
interventions (established or experimental). How can this status transition be
ethically accounted for in the BDA era? A consent form for infectious disease
research should reflect this transition and explain the context-dependent nature of
the terms that are used in research. BDA should be able to accommodate the
complexity arising from the possibility for patients to appear with a perceived
duality of status (infecting and infected) at the same time, both at the individual
and the population level.
Furthermore, the algorithms that enable profiling can ignore outliers (e.g. by
reverting to mean) and provide the basis for (intentional or unintentional) discrimina-
tion among individuals or groups by downstream policy makers and implementers. As
profiling (or at least some approximation) is inevitable—it is after all a very practical
approach in order to rationalize the vast amounts of information into actionable
information—how can individuals and group identities and differentiators be
protected? Can there be safeguards in place to protect the predictable becoming
exploitable? In order to achieve fairness and transparency, individuals should be made
aware that decisions were taken by including profiling algorithms. There should be
provision for meaningful information on the BDA approaches used and the assurance
that the individual view point can be expressed, that a challenge of the decision-making
through profiling will not impact future healthcare provision and that an alternative
human intervention can be provided.
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3.4 Surveillance and Behaviour
If effective infectious disease control policies are to be implemented in a given
population, the surveillance of outbreaks needs to be coupled through BDA with
modelling that predicts an individual’s or a group’s behaviour. Healthcare organizations
can have the technological ability for the first time to continuously observe and monitor
behaviours through mobile phone apps or wearable devices, offering personalized
services and advice, which may imply that these individuals are no longer exposed to
all options and choices that would normally be available. Is the pre-defined reduction of
free choice acceptable when coupled by more effective (in terms of treatment outcome)
and efficient healthcare options? This can only be decided on a case by case basis,
where the reduction of free choice is coupled by specific measure to safeguard
fundamental rights and the interests of the individual.
There is a substantial body of work relating to the factors that can influence
population behaviour in the field of infectious diseases, using specific language to
influence emotions leveraging anticipated behaviours, such as higher uptake of vacci-
nation or reduction of contact in public spaces (Bayham et al. 2015; Chapman and
Coups 2006)—and how altered social behaviour can then make a real difference in the
transmission of an infectious disease within a given population (Kucharski et al. 2014;
Funk et al. 2009). The impact of BDA is only expected to provide more and better
calibrated opportunities to influence behaviour. Is it then ethical to control or influence
an individual’s or group’s behaviour using information derived from their healthcare-
related big data? The response to this question would inevitably be context specific and
would relate to the relative balance between substantial public interest and potential
harm. The proportionate nature of the pursued aim should be made transparent—even
if that includes a high level of uncertainty, such as in the case of the recent Zika virus
outbreaks in South America.
Additionally, the need for quick actionable advice close to real-time, (e.g. during
international sports events; see Schenkel et al. 2006; Franke et al. 2006), regular
cultural events, (e.g. during the Hajj; see Memish 2009) or routine operations (e.g.
hospital emergency departments admissions; see Muscatello et al. 2005; Heffernan
et al. 2004) complicate things further. Complexities that involve real-time predictive
modelling are being addressed for unexpected and difficult to predict patterns, (e.g.
climatic conditions; see Sultan 2005; Keller et al. 2009) or one-off and high-impact
events (e.g. potential bioterrorist acts; see Kortepeter et al. 2000; Buehler et al. 2003).
Recently, the effects of novel computing techniques and implementations have started
to emerge. Algorithms can provide automated decision support as part of clinical
workflow at the time and location of the decision-making, without requiring clinician
initiative, and hence leading to cost and service improvements (Darrell et al. 2015). For
example, as part of implementing hospital-wide analytical decision-making tools,
patients presenting in emergency rooms are entered into an electronic health records
system, where an algorithm can evaluate their suitability for seasonal flu vaccinations.
This, in turn, prompts clinical staff to offer it, leading to a greater uptake of the vaccine
and downstream savings (Venkat et al. 2010). The possibility of implementing real-
time, responsive and adaptive calculations has great potential and is therefore very
tempting. However, because of its direct impact on the provision of care and its
resourcing in sometimes unpredictable ways, as well as its automated nature, it presents
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ethicists and regulatory bodies with challenges. These centre on the potential pressures
of reduced autonomy and choice, the difficulties of obtaining consent or potential for
automated ‘lack of consent’ policies and even, as a worst-case scenario, the potential
for unintentional harm.
4 Considerations and Recommendations
BDA has the potential to act as a catalyst and transformative agent in healthcare
introducing a new era of data utilization, particularly in the field of infectious diseases.
However, the ethical implications are not fully explored and if not addressed might
become limiting factors preventing BDA from reaching its full potential. There are
three further aspects that will be considered in this section, relating to the future
developments of the BDA applications in the field of infectious diseases.
Transdisciplinary View of BDA Ethics Impact A large number of studies on BDA in
healthcare reflect the uni-professional legacy of medical training and funding, yet there
is a call for more collaboration between medical, life and computational sciences—
often termed as ‘convergent’ or ‘inter-professional’ approach (Sharp et al. 2016; Nelson
and Staggers, 2017). Such ‘convergence’ has obvious potential for new discoveries. It
also requires the integration of historically distinct disciplines, technologies and ethical
viewpoints into a new unified whole. The further development of BDA ethics in
infectious disease will need to include an understanding of different users’ needs and
capabilities, of the technologies and of the problems investigated. BDA can accommo-
date and perhaps be even more effective if studies conducted were based on transdis-
ciplinary and participatory consultation designs, especially because there are so many
questions yet to be defined and researched.
For example, one could conduct studies where patients would have the right to
access their data, see their diagnosis/prognosis and have the ability to add their response
to it (therefore both meant to collect data and intervene at the same time). These patient
responses can then be used as validation inputs for BDA-based patient profiling, with
the patient once again having the opportunity to view this information, applying a
consistent, transparent approach throughout the patient contact points. A number of
such initiatives have already taken place at different areas of the developed world.
However, the usefulness of this approach is still hard to quantify as the outcome metrics
used were implemented within short time frames. Additionally, there is a lack of
rigorous empirical testing that can separate the effect of record access from other
existing disease management programs (de Lusignan et al. 2014; Jilka et al. 2015).
However, it should be noted that the traditional metrics used for the impact of
infectious diseases outbreaks still measure and report to a large extent the immediate
medical impact of outbreaks—not the wider socio-economic implications. This is done
for a number of reasons, such as the available infrastructure, the availability of skilled
labour and the existing reporting structures, which are not able to measure the wider
impact of infectious diseases outbreaks. (Heyman et al. 2015; Kruk et al. 2015) As
such, any improvements to traditional approaches—through BDA or other means—do
carry a potential multiplier effect in terms of their impact, where a moderate improve-
ment in clinical outcome is still considerable within a wider socioeconomic context.
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The information provided through this transdisciplinary view can include, inform and
improve the ethical arguments made in relation to the public good.
Ethical Considerations Are a Competitive Advantage In the case of established
infectious disease operations, the speed of technological development and the incorpo-
ration of new technologies, such as mobile phones and wearables, have outpaced the
adaptability of current frameworks. For example, there is still a very slow uptake within
healthcare of mobile phone-enabled appointment systems, even though the technology
has existed for over a decade. Especially in the heavily regulated sector of healthcare
provision, the speed of development and lack of flexibility demonstrate the need for
further work in the field. One example of this type of discourse is the creation and
world-wide distribution of thousands of healthcare-related applications. The majority of
those are created by individuals or private providers, not institutions, and very few are
regulated or if they are, they might conform to local regulations that may conflict within
different regions globally. The availability and uptake of applications where individuals
may voluntarily input part of their medical record has not been highlighted widely as a
potential ethical minefield, even though it presents challenges not only in terms of
provision of erroneous information, but also in terms of downstream personal infor-
mation usage. Mobile phone diagnostics developed by healthcare providers and vali-
dated through the implementation of international standards are also present into this
highly competitive melee. The FDA does not regulate applications that—in case of
malfunction—do not pose a health threat to others. As such, thousands of health-
related, data-rich applications remain without any regulation (Husain and Spence
2015). In light of this regulatory gap, addressing the rounded consideration of ethics
can serve an acute competitive advantage for the application developer (Gibbs et al.
2016) and as a pre-condition for wider adoption into the healthcare provision system.
Open Data Policy and Education The open data movement involves governments
and large public and private organizations making many of their datasets publicly
available, preferably in structured machine readable formats. The underlying drive for
this concept is that individual citizens, private sector and non-governmental organiza-
tions will, on a self-service basis, access and exploit these resources. However, the
description of each individual is contextually dependent and informationally inexhaust-
ible: i.e. there is no end to the potential use of one’s data once created; data can be
generalized, aggregated, defined, refined, repurposed, profiled and so on. The under-
standing of digital risks and ethical implications is lacking and should become a
substantial part of open data or of data collection practices and of digital literacy
training courses. As the information for an individual person is aggregated multiple
times with information for many other millions of individuals and parameters, and
information is extracted at multiple levels, understanding the pathway and processing
of data becomes increasingly difficult for individuals to attain. In much the same
manner, the attribution of accountability in the case of unintended harm through the
same means becomes difficult to ascertain. As such, the recommended approach would
be that of (ideally) introducing appropriate permissions for information generators and/
or custodians at the point of data release and pursue transparency thereof, so that the
information flow can be mapped, followed and its use audited if necessary or possible.
Where knowledge dissemination is the only realistic potential benefit, e.g. following
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infectious disease surveillance audits, researchers’ ethical obligations need to include
the understanding and description of potential collective risks in addition to the often
mentioned individual identification risks.
In summary, the BDA implementation in the field of infectious diseases seems as an
inevitable technological development. However, the long-term, widespread acceptance
of this addition to the clinical decision-making process and adoption by patients,
clinicians and the society needs to take into account the ethical aspects that are
augmented or created through BDA. The need for transdisciplinary approaches to
address urgent and/or complex situations should be inclusive of a transdisciplinary
view of ethical needs as well. The inclusion of patients into the participatory study
design and medical record access has allayed fears so far on the potential unethical use
of their data through BDA. However, there are as yet no consensus metrics against
which such opinions can be recorded, measured and addressed consistently. The
identification of potential ethical risks at an individual and group level through BDA
in infectious diseases should be a common feature, including the recognition of the
contextual nature of potential ethical risks. The above are mainly viewed through the
lens of the public healthcare provision; however, there are equally applicable in the case
of private healthcare providers that use BDA. The latter have made great strides to
develop data safety features as commercially exploitable competitive advantage and is
perhaps equally relevant that the inclusion of ethical considerations can become an
additional unique selling point.
5 Conclusions
The infectious diseases field’s obvious mission is to provide the best possible care for
infected individuals in the most efficient way, reduce the risk of outbreaks occurring
and/or control existing ones. The less obvious mission is to develop preparedness for
future outbreaks. The latter can be achieved through large -scale modelling and BDA
utilization (Rocha and Masuda 2016). BDA in infectious diseases has not been
designed as an inclusive tool, rather as a faster enabler of existing tools. The increasing
availability of information through many non-traditional channels requires increased
inclusivity and transparency along the needs for privacy and security. A significant
number of studies have been undertaken in order to solve issues of privacy and security
from a technological point of view (Safavi 2014; Camaraa 2015). That said more
studies need to take place and define the ethical implication of BDA in infectious
diseases in terms of (i) loss of individual autonomy and erosion of freedom of choice in
response to population-level benefits and the (ii) inclusion of ethical design in the
creation of BDA-enabled application aiding decision-making in healthcare provision.
The success of these actions would be the wide understanding for the contextual nature
of the BDA-aided interpretation and the relative risk-/benefit-based decision during
infectious disease outbreaks, not just by clinicians but by the wider society affected by
those outbreaks.
It is apparent that despite the positive impacts and advantages of BDA in the field of
infectious diseases, the overall consequences for individuals, groups, healthcare pro-
viders and society as a whole remain poorly understood and are an under-researched
topic. Importantly, an improved awareness and understanding of the ethical issues and
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consequences is required to avoid the emergence of a potential negative feedback loop,
where misunderstandings and lack of transparency can lead to social rejection, distorted
policy and to a lack of acceptance of new technologies—limiting their potential impact
for individual and societal well-being.
The surveillance potential, accuracy and immediacy of mobile-enabled technologies
need to be better understood, in terms of healthcare and social impacts, including the
ways in which this technology might be used for ‘social sorting’, such as the catego-
rization of people according to risk, which can have serious real-world consequences
(Lyon 2003). Irrespective of emergencies during infectious disease outbreaks, where
perhaps the established state or societal norms may be temporarily suspended, the
everyday potential benefits of mobile-enabled data collections need to be better bal-
anced against their potential threats to health, freedom, non-discrimination and privacy.
One should emphasize at this point that what is now considered ‘big data’ might be
only small data in decades to come. As such, the ethical pressures are expected to intensify
further. The current work has highlighted the impact of BDA on the ethics of infectious
diseases, as these might present themselves through established and novel perspectives.
As the application of BDA in this field is expanding, further work will be necessary to
define and address the ethical questions that will arise, as well as to implement consistent
transparency to cultivate public trust in these evolving hyper-complex situations.
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